2021
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR status
2018
Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas
Li H, Park HS, Osborn HA, Judson BL. Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas. Cancers Of The Head & Neck 2018, 3: 4. PMID: 31093357, PMCID: PMC6460664, DOI: 10.1186/s41199-018-0031-y.Peer-Reviewed Original ResearchSquamous cell carcinomaNational Cancer DatabaseOverall survivalOral cavityHPV cancersCell carcinomaHPV-negative squamous cell carcinomaOral cavity squamous cell carcinomaOP SCCHigh-risk human papillomavirusImproved overall survivalRetrospective cohort studyHigh-risk HPVDistinct clinical entityHuman papilloma virusLog-rank testKaplan-Meier estimatesOral cavity sitesChi-square testHPV carcinogenesisWorse OSCohort studyHPV statusRisk HPVClinical entity
2017
Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International Journal Of Gynecological Cancer 2017, 27: 1904-1911. PMID: 28763364, DOI: 10.1097/igc.0000000000001095.Peer-Reviewed Original ResearchConceptsReceipt of chemotherapyEndometrioid endometrial carcinomaNational Cancer Data BaseImproved overall survivalRole of chemotherapyOverall survivalAdjuvant chemotherapyAdjuvant treatmentStage II endometrial cancerCox proportional hazards regressionPropensity scoreAdjuvant therapy useGrade 3 diseaseStage II patientsProportional hazards regressionWorse overall survivalMultivariable logistic regressionKaplan-Meier estimatesLog-rank testAdjuvant radiotherapyExcellent prognosisLymphovascular invasionObservational cohortEEC patientsEndometrial cancer
2016
A Novel Prognostic Index for Ocular Adnexal Lymphoma
Meeks M, Park H, Yu J, Roberts K, Foss F, Wilson L. A Novel Prognostic Index for Ocular Adnexal Lymphoma. Blood 2016, 128: 3597. DOI: 10.1182/blood.v128.22.3597.3597.Peer-Reviewed Original ResearchOcular adnexal lymphomaNovel prognostic indexOverall survivalIndolent histologiesPrognostic indexRelative survivalAdnexal lymphomaGroup IIGroup IGroup I. Group IEnd Results (SEER) databaseSuperior overall survivalCohort of patientsProportional hazards analysisKaplan-Meier estimatesLacrimal gland tumorsHeterogeneous patient populationLarge national databaseAggressive histologyDistant diseaseConjunctival tumorsHazard ratioPrognostic factorsRare malignancyIndependent predictorsWho benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base
Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.Peer-Reviewed Original ResearchConceptsAdvanced endometrial cancerImproved overall survivalNational Cancer Data BaseOverall survivalHistologic gradeEndometrial cancerCox proportional hazards regressionPropensity scoreMultivariable subgroup analysisSignificant OS benefitGrade 1 patientsProportional hazards regressionKaplan-Meier estimatesLog-rank testLack of benefitOS benefitAdjuvant therapyStage IIIAStage IVAFIGO stageAdjuvant CRTHazards regressionTumor sizeRegional radiotherapySubgroup analysis